Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Current Leases data on file, last reported at $12.0 million in Q4 2025.

• Quarterly Current Leases rose 20.0% year-over-year to $12.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.0 million (up 20.0% YoY) and the FY2025 annual result came in at $12.0 million, up 20.0% from the prior year.
• Current Leases eased to $12.0 million in Q4 2025 per RARE's latest filing, from $12.1 million in the prior quarter.
• Across five years, Current Leases topped out at $12.8 million in Q1 2024 and bottomed at $9.4 million in Q1 2021.
• The 5-year median for Current Leases is $11.5 million (2022), against an average of $11.3 million.
• The widest annual swing landed in 2021, when Current Leases surged 37.42%; it then slipped 20.6% in 2024.
• Tracing RARE's Current Leases over 5 years: stood at $11.1 million in 2021, then gained by 6.44% to $11.8 million in 2022, then advanced by 6.93% to $12.6 million in 2023, then fell by 20.6% to $10.0 million in 2024, then climbed by 20.0% to $12.0 million in 2025.
• Per Business Quant, the three latest RARE Current Leases figures stand at $12.0 million (Q4 2025), $12.1 million (Q3 2025), and $11.8 million (Q2 2025).

Peer Comparison